Nutra Pharma Corp. NPHC

Company Overview

Nutra Pharma Corp. is a U.S.-based biotechnology and specialty pharmaceutical company that has historically focused on the development of treatments derived from venom-based compounds, particularly for neurological and autoimmune conditions. The company has operated primarily in the biopharmaceutical and nutraceutical sectors, with public disclosures emphasizing research into pain management therapies, multiple sclerosis-related treatments, and immune-related disorders. Public filings and market disclosures indicate that the company has also explored over-the-counter health products and dietary supplement commercialization activities at various points in its operating history.

The company’s principal strategic positioning has centered on the licensing, development, and commercialization of venom-derived pharmaceutical technologies. Historically, Nutra Pharma promoted intellectual property associated with cobra venom analgesics and autoimmune therapeutics through subsidiaries including ReceptoPharm, Inc. and Cobra Venom Medicine, Inc. The company evolved from a broader nutraceutical orientation into a more specialized biotechnology-focused enterprise, although public disclosures over time have reflected fluctuating operational scale, financing constraints, and varying levels of commercial activity. Data regarding sustained commercial revenue generation and long-term product commercialization remains inconclusive based on available public sources.